These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 22190683)

  • 1. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation.
    Kim W; Kim R; Park G; Park JW; Kim JE
    J Biol Chem; 2012 Feb; 287(8):5588-99. PubMed ID: 22190683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.
    Kim W; Choi M; Kim JE
    Cell Cycle; 2014; 13(5):726-38. PubMed ID: 24526115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure.
    Jones B; Su H; Bhat A; Lei H; Bajko J; Hevi S; Baltus GA; Kadam S; Zhai H; Valdez R; Gonzalo S; Zhang Y; Li E; Chen T
    PLoS Genet; 2008 Sep; 4(9):e1000190. PubMed ID: 18787701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dot1L mediated histone H3 lysine79 methylation is essential to meiosis progression in mouse oocytes.
    Wang X; Gao W; Ma X; Wang X; Song C; Huang X; Liu H
    Neuro Endocrinol Lett; 2014; 35(6):523-30. PubMed ID: 25433842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
    Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
    Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
    Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
    J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
    Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
    Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases.
    Wakeman TP; Wang Q; Feng J; Wang XF
    EMBO J; 2012 May; 31(9):2169-81. PubMed ID: 22373577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.
    Zhang L; Deng L; Chen F; Yao Y; Wu B; Wei L; Mo Q; Song Y
    Oncotarget; 2014 Nov; 5(21):10665-77. PubMed ID: 25359765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.
    Chen S; Yang Z; Wilkinson AW; Deshpande AJ; Sidoli S; Krajewski K; Strahl BD; Garcia BA; Armstrong SA; Patel DJ; Gozani O
    Mol Cell; 2015 Oct; 60(2):319-27. PubMed ID: 26439302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diverse functions of Dot1 and H3K79 methylation.
    Nguyen AT; Zhang Y
    Genes Dev; 2011 Jul; 25(13):1345-58. PubMed ID: 21724828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
    Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
    Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
    Vlaming H; McLean CM; Korthout T; Alemdehy MF; Hendriks S; Lancini C; Palit S; Klarenbeek S; Kwesi-Maliepaard EM; Molenaar TM; Hoekman L; Schmidlin TT; Altelaar AM; van Welsem T; Dannenberg JH; Jacobs H; van Leeuwen F
    EMBO J; 2019 Jul; 38(14):e101564. PubMed ID: 31304633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOT1L and H3K79 Methylation in Transcription and Genomic Stability.
    Wood K; Tellier M; Murphy S
    Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29495487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the DNA damage response and gene expression by the Dot1L histone methyltransferase and the 53Bp1 tumour suppressor.
    FitzGerald J; Moureau S; Drogaris P; O'Connell E; Abshiru N; Verreault A; Thibault P; Grenon M; Lowndes NF
    PLoS One; 2011 Feb; 6(2):e14714. PubMed ID: 21383990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions.
    Ho LL; Sinha A; Verzi M; Bernt KM; Armstrong SA; Shivdasani RA
    Mol Cell Biol; 2013 May; 33(9):1735-45. PubMed ID: 23428873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted disruption of the histone lysine 79 methyltransferase Dot1L in nephron progenitors causes congenital renal dysplasia.
    Wang F; Ngo J; Li Y; Liu H; Chen CH; Saifudeen Z; Sequeira-Lopez MLS; El-Dahr SS
    Epigenetics; 2021 Nov; 16(11):1235-1250. PubMed ID: 33315499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare de novo gain-of-function missense variants in DOT1L are associated with developmental delay and congenital anomalies.
    Nil Z; Deshwar AR; Huang Y; Barish S; Zhang X; Choufani S; Le Quesne Stabej P; Hayes I; Yap P; Haldeman-Englert C; Wilson C; Prescott T; Tveten K; Vøllo A; Haynes D; Wheeler PG; Zon J; Cytrynbaum C; Jobling R; Blyth M; Banka S; Afenjar A; Mignot C; Robin-Renaldo F; Keren B; Kanca O; Mao X; Wegner DJ; Sisco K; Shinawi M; ; Wangler MF; Weksberg R; Yamamoto S; Costain G; Bellen HJ
    Am J Hum Genet; 2023 Nov; 110(11):1919-1937. PubMed ID: 37827158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation.
    Cao K; Ugarenko M; Ozark PA; Wang J; Marshall SA; Rendleman EJ; Liang K; Wang L; Zou L; Smith ER; Yue F; Shilatifard A
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27365-27373. PubMed ID: 33077595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The upstreams and downstreams of H3K79 methylation by DOT1L.
    Vlaming H; van Leeuwen F
    Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.